cobimetinib (Cotellic®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation (in combination with vemurafenib)

All of the following must be met as a condition for coverage:

  • Treatment of unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation (in combination with vemurafenib)

This Medication is Not Approvable for the following condition(s):

  • Any condition not listed above as an approved indication

Dosing:

FDA-approved uses

  • Melanoma, unresectable or metastatic (with BRAF V600E or V600K mutations)
Usual dosage
  • 60 mg once daily days 1 to 21 of each 28-day treatment cycle (in combination with vemurafenib)

Dosage adjustment

  • Recommended cobimetinib dose reductions for toxicity (vemurafenib may also require dosage adjustment):
    • First dose reduction: 40 mg once daily
    • Second dose reduction: 20 mg once daily
    • Subsequent modification (if unable to tolerate 20 mg once daily): Permanently discontinue

Approval:

One year


 

Last review date: July 25, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar